[ALDR] Alder BioPharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 22.5 Change: 1.45 (6.89%)
Ext. hours: Change: 0 (0%)

chart ALDR

Refresh chart

Strongest Trends Summary For ALDR

ALDR is in the medium-term down -18% below S&P in 7 months. In the long-term down -85% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alder Biopharmaceuticals Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes various therapeutic antibodies in the United States and Australia. It is developing monoclonal antibodies comprising ALD403, which has completed Phase Ib proof-of-concept trials to target calcitonin gene-related peptide for the prevention of migraine; and Clazakizumab that has completed Phase IIb clinical trials that inhibits the pro-inflammatory cytokine interleukin-6 in the treatment of rheumatoid arthritis and psoriatic arthritis. The company also has preclinical programs in the discovery phase for various indications. Alder Biopharmaceuticals Inc. has a collaboration with Bristol-Myers Squibb Company for the development of Clazakizumab. Alder Biopharmaceuticals Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Fundamental Ratios
Shares Outstanding EPS-4.47 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-3.91
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-0.14% ROE-0.15% ROI
Current Ratio36.49 Quick Ratio Long Term Debt/Equity Debt Ratio0.03
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities190.83 M Cash From Investing Activities-11.65 M Cash From Operating Activities-16.05 M Gross Profit
Net Profit-14.65 M Operating Profit-14.71 M Total Assets242.94 M Total Current Assets241.6 M
Total Current Liabilities6.62 M Total Debt Total Liabilities6.78 M Total Revenue
Technical Data
High 52 week18.6 Low 52 week9.8 Last close10.83 Last change-1.37%
RSI17.39 Average true range0.63 Beta1.7 Volume534.94 K
Simple moving average 20 days-12.1% Simple moving average 50 days-16.25% Simple moving average 200 days-19.11%
Performance Data
Performance Week-4.58% Performance Month-15.26% Performance Quart-24.37% Performance Half-17.83%
Performance Year-35.15% Performance Year-to-date5.66% Volatility daily3.36% Volatility weekly7.51%
Volatility monthly15.39% Volatility yearly53.32% Relative Volume264.97% Average Volume1.07 M
New High New Low

News

2019-09-20 17:00:00 | CBM, SEMG, ALDR: Monteverde & Associates PC Reminds Investors of an Ongoing Inquiry Regarding the Acquisition

2019-09-19 12:51:59 | ALDR, MAMS, BKJ, and SRCI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

2019-09-18 10:33:02 | Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More

2019-09-17 21:45:00 | SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Alder BioPharmaceuticals, Inc. - ALDR

2019-09-17 18:14:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Alder Biopharmaceuticals, Inc.

2019-09-17 12:29:15 | A Look At Benzinga Pro's Most-Searched Tickers For September 17, 2019

2019-09-17 10:44:43 | Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – PVTL, UCFC, SEMG, ALDR

2019-09-17 10:29:02 | Company News For Sep 17, 2019

2019-09-17 09:26:01 | Alder ALDR Stock Up on Acquisition Agreement With Lundbeck

2019-09-17 07:23:23 | The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study

2019-09-16 16:17:38 | This Biotech Stock Just Rocketed 84% On A $2 Billion Takeover Deal

2019-09-16 13:22:00 | Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Alder BioPharmaceuticals, Inc. NASDAQ: ALDR on Behalf of Alder Shareholders and Encourages Alder Investors to Contact the Firm

2019-09-16 13:15:42 | A Look At Benzinga Pro's Most-Searched Tickers For September 16, 2019

2019-09-16 12:45:00 | ALDER BIOPHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

2019-09-16 12:22:16 | Alder Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Alder Biopharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact The Firm – ALDR

2019-09-16 11:09:00 | Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Alder BioPharmaceuticals has obtained a Fair Price in its sale to H. Lundbeck A/S

2019-09-16 10:19:31 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Alder BioPharmaceuticals, Inc. to H. Lundbeck A/S is Fair to Shareholders

2019-09-16 09:19:43 | Danish Company To Buy Migraine Drug Developer Alder Biopharma In Deal Worth Up To $1.95B

2019-09-16 08:29:00 | Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout deal

2019-09-16 07:46:00 | Alder ALDR Alert: Johnson Fistel Investigates Proposed Sale of Alder BioPharmaceuticals, Inc.; Are Shareholders Getting a Fair Deal?

2019-09-16 05:31:00 | [video]Alder Biopharmaceuticals Surges on Lundbeck Offer

2019-09-16 02:10:06 | Lundbeck to buy migraine treatment developer Alder BioPharmaceuticals

2019-09-16 01:55:52 | Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash

2019-09-10 10:29:02 | Alder BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

2019-09-05 16:01:00 | Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society

2019-09-04 09:00:00 | Bolt Biotherapeutics Appoints Veteran Executive Randall Schatzman as CEO to Lead the Next Phase of Growth

2019-08-30 16:01:00 | Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635c4

2019-08-28 16:01:00 | Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences

2019-08-22 12:01:04 | MyoKardia Begins Dosing in Phase I Study on Heart Candidate

2019-08-21 11:08:03 | NuCana Stops Patient Enrollment in Pancreatic Cancer Study

2019-08-16 11:23:03 | What's in Store for Aytu BioScience's AYTU Q4 Earnings?

2019-08-15 20:12:51 | Alder BioPharmaceuticals approaches rare status for a Seattle biotech

2019-08-15 20:12:51 | Alder on hiring binge ahead of FDA ruling

2019-08-07 19:48:17 | Alder BioPharmaceuticals, Inc. ALDR Q2 2019 Earnings Call Transcript

2019-08-07 03:34:09 | Edited Transcript of ALDR earnings conference call or presentation 6-Aug-19 9:00pm GMT

2019-08-06 16:07:00 | Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results

2019-08-02 16:01:00 | Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-08-01 08:01:00 | Alder BioPharmaceuticals® to Present at Canaccord Genuity 39th Annual Growth Conference

2019-07-30 16:01:00 | Alder BioPharmaceuticals® to Host Conference Call to Discuss Second Quarter 2019 Financial and Operating Results

2019-07-26 16:01:00 | Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635c4

2019-07-19 09:57:01 | Alder Biopharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

2019-07-11 08:00:00 | Alder BioPharmaceuticals® Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention

2019-07-08 08:00:00 | Alder BioPharmaceuticals® to Showcase 14 New Data Presentations Demonstrating Eptinezumab’s Migraine Prevention and Quality of Life Impact at American Headache Society Meeting

2019-07-03 09:00:01 | All You Need to Know About Alder BioPharmaceuticals ALDR Rating Upgrade to Buy

2019-06-29 23:32:04 | Is Alder Biopharmaceuticals Inc ALDR A Good Stock To Buy ?

2019-06-19 08:01:00 | Alder BioPharmaceuticals® to Webcast Upcoming Breakfast Symposium with Key Opinion Leaders

2019-06-18 16:01:00 | Alder BioPharmaceuticals® to Present at BMO Capital Markets 2019 Prescription for Success Healthcare Conference

2019-06-11 08:02:54 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

2019-06-10 08:05:19 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

2019-06-04 14:18:53 | Imagine Owning Alder BioPharmaceuticals NASDAQ:ALDR While The Price Tanked 65%